Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings

Abstract

Background Medicines that are based on known molecules and are further developed to address healthcare needs and deliver relevant improvement for patients, healthcare professionals and/or payers are called value-added medicines (VAMs). The evaluation process of VAMs is heterogeneous across countries, and it has been primarily designed for originator pharmaceuticals with confirmatory evidence collected alongside pivotal clinical trials. There is a mismatch between evidence requirements by public decision-makers and evidence generated by manufacturers of VAMs. Our objective was to develop a core evaluation framework for VAMs. Methods Potential benefits offered by VAMs were collected through a systematic literature review and allocated to separate domains in an iterative process. The draft list of domains and their applicability were validated during two consecutive virtual workshops by health policy experts representing countries with different economic statuses, geographical and decision-making contexts. Results Based on 158 extracted studies, the final consensus on the evaluation framework resulted in 11 value domains in 5 main clusters, including unmet medical needs, health gain (measured by health care professionals), patient-reported outcomes, burden on households, and burden on the health care system. Conclusions The proposed framework could reduce the heterogeneity in value assessment processes across countries and create incentives for manufacturers to invest in incremental innovation. However, some domains may not be equally relevant or accepted in all countries, therefore the core framework needs thorough adaptation in specific jurisdictions.

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia

“…Policy tools that can increase price competition among off-patent medicines by generic substitution, along with internal and external price referencing, are evident in many countries ( Kaló et al, 2021 ). The key target for public healthcare payers is to reinforce the allocative efficiency of healthcare costs ( Inotai et al, 2017 ; Petykó et al, 2021 ). The aim of an off-patent drug policy, considering that patients have full access to the original or reference medicines prior to their patent expiry, is usually characterized by reducing health expenditures without compromising health benefits ( Kaló et al, 2015 ).…”

Digital Era for Quality Education: Effectiveness of Discovery Learning with Android to Increase Scientific Literacy

“…Literature review research is the result of analysis of various conceptual information and qualitative and quantitative data from various previously published scientific articles. scientific literacy (Petyko et al, 2021).…”

“…This literature review uses international and national journals for the 2018-2023 publication range. The framework of the literature study includes identification, screening of titles and abstracts, complete literature review, data extraction, analysis, and conclusion-making adopted from Petyko et al (2021), according to Figure 1.…”

Implementation of ESD (Education for Sustainable Development) in Climate Change Learning: A Literature Review

“…The articles/journals were published within the last five years, between 2017 and 2022. The framework for the literature study procedure for applying ESD in climate change learning adapted from Petyko et al (2021) includes identification, screening of titles and abstracts, a full review of literature, data extraction, analyzing, and making conclusions likely in Figure 1. (Petyko et al, 2021).…”